caa a22 4500 475832868 CHVBK 20180406123845.0 cr unu---uuuuu 170329e20000301xx s 000 0 eng 10.1007/s100960050446 doi (NATIONALLICENCE)springer-10.1007/s100960050446 In Vitro Susceptibility to Gemifloxacin and Trovafloxacin of Streptococcus pneumoniae Strains Exhibiting Decreased Susceptibility to Ciprofloxacin [Elektronische Daten] [F. Fuentes, M. J. Giménez, F. Marco, L. Alou, L. Aguilar, J. Prieto]  The in vitro susceptibility to trovafloxacin and gemifloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin (MIC ≥2 μg/ml; 30 strains with intermediate resistance [MIC 2 μg/ml] and 43 strains with complete resistance [MIC ≥4 μg/ml]) was determined. Seventy-three strains collected in a surveillance study carried out from May 1996 to April 1997 in Spain (prior to commercialisation of trovafloxacin and gemifloxacin) from patients with respiratory tract infections were tested. The antibacterial activity of gemifloxacin was affected to a lesser extent than that of trovafloxacin by the increase in the MIC of ciprofloxacin, with gemifloxacin showing significantly (P≤0.001) better antibacterial activity than trovafloxacin in all ciprofloxacin MIC categories (MIC50/MIC90 values of 0.015/0.03, 0.015/0.06, 0.03/0.06 and 0.12/0.25 μg/ml for gemifloxacin vs 0.12/0.12, 0.12/1, 0.25/0.5 and 2/4 μg/ml for trovafloxacin in the 2, 4, 8 and ≥16 μg/ml ciprofloxacin MIC categories, respectively). Nine (12.3%) of these 73 strains exhibited decreased susceptibility to trovafloxacin (≥2 μg/ml), whereas all strains were inhibited by 0.25 μg/ml of gemifloxacin. Springer-Verlag Berlin Heidelberg, 2000 Fuentes F. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut Giménez M. J. Medical Department, SmithKline Beecham Pharmaceuticals, Valle de la Fuenfría 3, 28034 Madrid, Spain e-mail: lorenzo.aguilar-alfaro@sb.com, ES aut Marco F. Microbiology Department, Hospital Clinic i Provincial, Villarroel 170, 08036 Barcelona, Spain, ES aut Alou L. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut Aguilar L. Medical Department, SmithKline Beecham Pharmaceuticals, Valle de la Fuenfría 3, 28034 Madrid, Spain e-mail: lorenzo.aguilar-alfaro@sb.com, ES aut Prieto J. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut https://doi.org/10.1007/s100960050446 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s100960050446 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fuentes F. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut NATIONALLICENCE 700 1- Giménez M. J. Medical Department, SmithKline Beecham Pharmaceuticals, Valle de la Fuenfría 3, 28034 Madrid, Spain e-mail: lorenzo.aguilar-alfaro@sb.com, ES aut NATIONALLICENCE 700 1- Marco F. Microbiology Department, Hospital Clinic i Provincial, Villarroel 170, 08036 Barcelona, Spain, ES aut NATIONALLICENCE 700 1- Alou L. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut NATIONALLICENCE 700 1- Aguilar L. Medical Department, SmithKline Beecham Pharmaceuticals, Valle de la Fuenfría 3, 28034 Madrid, Spain e-mail: lorenzo.aguilar-alfaro@sb.com, ES aut NATIONALLICENCE 700 1- Prieto J. Microbiology Department, School of Medicine, Universidad Complutense, Avenida Complutense s/n, 28040 Madrid, Spain, ES aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer